GlassScriptPhysician profile
Robert G Lugo
NPI 1700179827
$2,542.14
in general payments reported to CMS, 2019-2025
24 companies · $848 in 2025
The $848 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.26 · 2020: $17.66 · 2021: $251 · 2022: $386 · 2023: $701 · 2024: $305 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Travel and Lodging: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.45 |
| Travel and Lodging | $475.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $622.59 | 2021-2023 | Nalu Neurostimulation System |
| Abbott Laboratories | $483.39 | 2022-2025 | Proclaim, Eterna |
| Saluda Medical Americas, INC. | $290.07 | 2025 | Evoke |
| Mml US, INC. | $244.68 | 2022 | |
| Exact Sciences Corporation | $149.51 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Insulet Corporation | $144.56 | 2025 | Omnipod, Omnipod |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $54.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.28 | 2019-2022 | |
| Nevro Corp. | $48.51 | 2021 | |
| Novo Nordisk INC | $42.00 | 2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $32.77 | 2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $29.49 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.59 | 2025 | Airsupra |
| Boston Scientific Corporation | $24.65 | 2023 | G4 Rf Generator |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21.77 | 2024 | |
| Astellas Pharma US INC | $21.76 | 2025 | Veozah |
| Lilly USA, LLC | $21.28 | 2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $19.50 | 2024 | Trelegy Ellipta |
| Abbvie INC. | $19.09 | 2022 | |
| Grt US Holding, INC. | $18.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.66 | 2020 | |
| Acadia Pharmaceuticals INC | $14.31 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lugo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.